FTC gets NAD case
This article was originally published in The Tan Sheet
Executive Summary
Advertising for PBM Products' Ultra Bright Beginnings infant formula will be referred to FDA and FTC since the company declined to participate in a NAD review, the National Advertising Division says March 24. The Council of Better Business Bureaus group requested substantiation for PBM's comparative superiority claims including "the highest DHA at a low price" and "more DHA than any brand." PBM also was asked to provide substantiation for implied claims that babies fed Bright Beginnings "will be smarter than babies fed with other formulas," NAD states...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.